Non-small cell lung cancer (NSCLC) poses a global health threat, and epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, afatinib, and …

Background Lung cancer is a highly prevalent malignancy with significant morbidity and
mortality rates. MiR-489–3p, a microRNA, has been identified as a regulator of tumor cell …

Background HER2-targeted therapy provides survival benefits to HER2-mutant non-small
cell lung cancer (NSCLC). A better understanding of the clinical and genomic …

Rapidly evolving targeted and immunotherapies in non-small cell lung carcinoma (NSCLC)
have resulted in an enormous pressure to develop and implement laboratory assays that will …

Microabstract Gene copy number is a continuous variable; the relevant cutpoint for HER2,
KRAS and MET copy number gain (CNG) in NSCLC remains uncertain. As de novo driver …

Background Although some targeted therapies have been shown to be effective in treating
HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been …

Structured abstract Background Real-world data for advanced/metastatic non-small cell lung
cancer (NSCLC) with mutations in human epidermal growth factor 2 (HER2) are scarce. We …

Lung cancer is a leading cause of cancer-related death worldwide in both men and women,
however mortality in the US and EU are recently declining in parallel with the gradual cut of …

Background The human epidermal growth factor receptor 2 gene (HER2) has been
identified as a potential therapeutic target in lung adenocarcinoma (LUAD). Non-invasive …

Background Patients with HER2-positive cancers often face a poor prognosis, and treatment
regimens containing anti-HER2 have become the first-line treatment options for breast and …